{
    "key_points": [
        "FDA expands eligibility for COVID-19 booster doses to individuals 18 years and older.",
        "Booster authorization applies to those who have completed primary vaccination with any FDA-authorized or approved COVID-19 vaccine.",
        "CDC's Advisory Committee on Immunization Practices to discuss further clinical recommendations.",
        "Acting FDA Commissioner Janet Woodcock emphasizes COVID-19 vaccines as highly effective defense.",
        "Prior authorization limited boosters to older adults, high-risk individuals, and those with frequent exposure to COVID-19.",
        "FDA's Peter Marks highlights the aim to streamline eligibility criteria and clarify booster availability.",
        "Booster dose EUA for Moderna and Pfizer-BioNTech vaccines based on immune response data analysis.",
        "Completed primary vaccination series provides strong, sustained, and broadly neutralizing antibodies.",
        "Vaccines expected to offer nearly 100% protection against secondary challenges from the pandemic strain.",
        "FDA and CDC emphasize vaccinations and precautions against respiratory pathogens."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of the FDA's Center for Biologics Evaluation and Research)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}